Amgen, FTC settlement allows $28B Horizon acquisition to move forward

The latest stories trending on MedCity News.

MedCity News' daily newsletter will be paused on Monday, September 4, in observance of Labor Day. It will resume on Tuesday, September 5.

Editor's Pick

Top Story Amgen, FTC Settlement Allows $28B Horizon Acquisition to Move Forward Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant's $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to "bundle" its products with Horizon's drugs in negotiations with health plans. Sponsored Content Next-Generation Proteomics Presented by Quantum-Si Quantum-Si's Platinum benchtop protein sequencer offers a simpler, more economical alternative to mass spectrometry. Learn More>>

Featured News

Data Access and Equity: How Secure Engagement Data Sharing Makes for Healthier Patients The fusion of clinical and engagement data can revolutionize the way we understand and treat patients. By optimizing data collection and synthesis, securely sharing data, and ensuring equitable access, we can make significant strides towards delivering more personalized, effective, and patient-centered care. Bicycle Health, Albertsons Form Partnership To Expand Access to OUD Treatment Through a new partnership, Bicycle Health providers can prescribe patients buprenorphine extended release injections (otherwise known as Sublocade), which can be administered by a pharmacist at an Albertsons pharmacy. What Do Value-Based Care Startups Need to Do to Attract Investors? As the value-based care market gets more crowded, startups in this space will have to nail down the fundamentals in order to attract capital from investors, healthcare business expert Paul Campbell said during a virtual conference. He encouraged startups to be crystal clear about what their value proposition is for three main stakeholders — patients, providers and payers.

Resources

MedCity Pivot Podcast: A Conversation With Unlearn.AI CEO About Clinical Trials The founder and CEO of Unlearn.AI seeks to make clinical trials more efficient and less costly by leveraging its Digital Twin technology. If the company is successful, drugs could potentially be brought to market sooner and in a cost effective manner. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe